SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Howard Henick who wrote (220)7/6/1998 1:22:00 AM
From: synchro  Respond to of 656
 
Whenever Hoestch has good news on its RA drug, Immunex seems to go into a tailspin. You could argue that the current IMNX has discounted its Enbrel RV treatment into the current price.



To: Howard Henick who wrote (220)7/6/1998 1:31:00 PM
From: LemurHouse  Read Replies (1) | Respond to of 656
 
How much of the revenue on Enbrel will be taken by AHP, and what will be left over for Immunex? I'm a little vague on what their marketing agreement is.

Any insight from threaders would be most appreciated.

Thanks.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News